GSK Clinical Trials Study Director GlaxoSmithKline
Kontakt
US GSK Clinical Trials Call Center Kontakt: Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com» Kontaktdaten anzeigen EU GSK Clinical Trials Call Center Kontakt: Phone: +44 (0) 20 89904466 E-Mail: GSKClinicalSupportHD@gsk.com» Kontaktdaten anzeigen
Studienlocations (3 von 35)
GSK Investigational Site 69120 Heidelberg (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 72076 Tuebingen (Baden-Württemberg) GermanyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 19049 Schwerin (Mecklenburg-Vorpommern) GermanyAbgeschlossen» Google-Maps
GSK Investigational Site 56068 Koblenz (Rheinland-Pfalz) GermanyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 01307 Dresden (Sachsen) GermanyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 20246 Hamburg (Hamburg) GermanyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 85364 Yuma United StatesRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 66205 Westwood United StatesRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 28204 Charlotte United StatesRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 53792 Madison United StatesRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 2298 Waratah AustraliaRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 3065 Fitzroy AustraliaRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site T6G 1Z2 Edmonton CanadaRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site N6A 5W9 London CanadaAbgeschlossen» Google-MapsGSK Investigational Site 86021 Poitiers cedex FranceRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 40138 Bologna ItalyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 47014 Meldola ItalyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 00161 Roma ItalyRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 137-701 Seoul, Korea Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 03080 Seoul Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 03722 Seoul Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 06351 Seoul Korea, Republic ofRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 20-081 Lublin PolandRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 61-848 Poznan PolandRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 08916 Badalona SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 08036 Barcelona SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 28027 Madrid SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 29010 Málaga SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 31008 Pamplona SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 28223 Pozuelo De Alarcón/Madrid SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site 39008 Santander SpainRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site SO16 6YD Southampton United KingdomAbgeschlossen» Google-MapsGSK Investigational Site OX3 7LE Headington, Oxford United KingdomRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site LE1 5WW Leicester United KingdomRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigenGSK Investigational Site SE1 9RT London United KingdomRekrutierend» Google-Maps Ansprechpartner: US GSK Clinical Trials Call Center Phone: 877-379-3718 E-Mail: GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Centre Phone: +44 (0) 20 8990 4466 E-Mail: GSKClinicalSupportHD@gsk.com» Ansprechpartner anzeigen
1. Number of participants with dose-limiting toxicities (DLTs) (Time Frame - Treatment cycle 1 to 3 (each cycle of 21 days)): The number of participants with DLTs will be reported.
2. Number of participants with adverse events (AEs) and serious adverse events (SAEs) (Time Frame - Up to an average of 54 months): AEs and SAEs will be collected.
Secondary outcome:
1. Lenalidomide relative dose intensity (RDI ) of treatment with belantamab mafodotin in combination with VRd (Time Frame - 4 treatment cycles (each cycle of 21 days)): RDI of treatment with belantamab mafodotin in combination with VRd will be analyzed.
2. Bortezomib RDI of treatment with belantamab mafodotin in combination with VRd (Time Frame - 4 treatment cycles (each cycle of 21 days)): RDI of treatment with belantamab mafodotin in combination with VRd will be analyzed.
3. Cumulative administered dose of belantamab mafodotin treatment in combination with VRd (Time Frame - 4 treatment cycles (each cycle of 21 days)): Cumulative administered dose of belantamab mafodotin in treatment in combination with VRd will be analyzed.
4. Maximum plasma concentration (Cmax) of belantamab mafodotin (Time Frame - Up to an average of 52 months): Blood samples will be collected at indicated time points for pharmacokinetic analysis.
5. Cmax of microtubule inhibitor monomethyl auristatin-F with a cysteine linker (cys-mcMMAF) (Time Frame - Up to an average of 52 months): Blood samples will be collected at indicated time points for pharmacokinetic analysis.
6. Area under the concentration time curve (AUC) of belantamab mafodotin (Time Frame - Up to an average of 52 months): Blood samples will be collected at indicated time points for pharmacokinetic analysis.
7. AUC of cys-mcMMAF (Time Frame - Up to an average of 52 months): Blood samples will be collected at indicated time points for pharmacokinetic analysis.
8. Number of participants with positive anti-drug antibodies (ADAs) against belantamab mafodotin (Time Frame - Up to an average of 52 months): Serum samples for the analysis of anti-belantamab mafodotin antibodies will be collected. The samples will be tested for anti-belantamab mafodotin antibodies using a tiered-testing scheme consisting of validated screening, confirmation, and titration assays.
9. Titers of ADAs against belantamab mafodotin (Time Frame - Up to an average of 52 months): Serum samples for the analysis of anti-belantamab mafodotin antibodies will be collected. The samples will be tested for anti-belantamab mafodotin antibodies using a tiered-testing scheme consisting of validated screening, confirmation, and titration assays.
10. Overall Response Rate (ORR) (Time Frame - Up to 52 months): ORR is defined as the percentage of participants with a confirmed partial response (PR) or better based on the response assessed by the investigator using International Myeloma Working Group (IMWG) criteria.
11. Complete Response Rate (CRR) (Time Frame - Up to 52 months): CRR is defined as the percentage of participants with a confirmed complete response (CR) or better based on the response assessed by the investigator using IMWG criteria.
12. Rate of Very Good Partial Response (VGPR) or better (Time Frame - Up to 52 months): Rate of VGPR or better is defined as the percentage of participants with a confirmed VGPR or better based on the response assessed by the investigator using IMWG criteria.
Experimental: Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd Participants will receive 1.9 milligram /kilogram (mg/kg) Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Experimental: Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd Participants will receive 1.4 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Experimental: Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd Participants will receive 1.9 mg/kg Q6W dose of belantamab mafodotin on Day 1 of every other cycle for the first 8 cycles in combination with VRd and Q8W dose in combination with Rd from cycle 9 onwards.
Experimental: Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd Participants will receive 1.0 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Experimental: Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd Participants will receive 1.4 mg/kg Q3W dose of belantamab mafodotin on Day 1 of every cycle for the first 8 cycles in combination with VRd and Q4W dose in combination with Rd from cycle 9 onwards.
Experimental: Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd Based on emerging data from Cohort 2-5, participants will receive 1.4 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1, followed by 1.0 mg/kg dose on Day 1 of every third cycle from cycle 4 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Experimental: Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd Based on emerging data from Cohort 2-5, participants will receive 1.9 mg/kg dose of belantamab mafodotin of cycle 1, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 4 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Experimental: Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd Based on emerging data from Cohort 6-7, participants will receive 1.9 mg/kg dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 4, followed by 1.4 mg/kg on Day 1 of every third cycle from cycle 7 onwards, in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Experimental: Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd Based on emerging data from Cohort 6-7, participants will receive 1.4 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 3, then 1.0 mg/kg on Day 1 of every third cycle from cycle 6 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Experimental: Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd Based on emerging data from Cohort 6-7, participants will receive 1.0 mg/kg IV dose of belantamab mafodotin on Day 1 of cycle 1 and cycle 5, then 1.0 mg/kg on day 1 of every third cycle from cycle 9 in combination with VRd for the first 8 cycles and in combination with Rd from cycle 9 onwards.
Belantamab mafodotin: Selected doses of belantamab mafodotin will be administered as intravenous infusion.
Bortezomib: Bortezomib will be administered subcutaneously or intravenously approximately 1 hour after the belantamab mafodotin infusion until Cycle 8.
Lenalidomide: Lenalidomide will be administered as 25 or 10 mg orally, depending upon renal function.
Dexamethasone: Dexamethasone will be administered orally as 20 mg in cycles 1-8 and 40 mg in Cycle 9 onwards.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!